PF-06412562

N/A

Report date: 2025/06/05 16:57:39
NME

Base Information

Drug NamePF-06412562
Drug Alias NamePF-6412562PF-06412562PF-2562CVL-562
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D1 receptor partial agonistsDopamine D5 receptor partial agonists
TargetsDopamine D1 receptorDopamine D5 receptor
Therapy Area/IndicationsSchizophreniaSchizophrenia Spectrum and Other Psychotic DisordersParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSweden
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesYale University
Inactive CompaniesPfizer IncInvicro Llc
Active IndicationsSchizophrenia Spectrum and Other Psychotic Disorders
Inactive IndicationsSchizophreniaParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A